基于Web of Science的PCSK9抑制剂在心血管治疗领域相关研究文献计量学分析

doi:10.5246/jcps.2025.03.018

摘要/Abstract

摘要：

本研究采用文献计量法全面分析前蛋白转化酶枯草溶菌素9 (pro-protein convertase subtilisin/kexin type 9, PCSK9)抑制剂在心血管疾病治疗领域的研究现状及发展趋势。计算机检索2013年1月1日–2023年12月31日在Web of Science核心合集数据库发表的关于PCSK9抑制剂在心血管疾病治疗领域的英文文献。该研究利用VOSviewer1.6.20、CiteSpace 6.2.R6和Excel 2021软件统计、分析相关研究的发文量、国家/地区、机构、作者、期刊、研究热点等文献关键特征。共检索到1383篇文献, 年发文量总体呈上升趋势; 共计78个国家/地区开展了相关研究, 其中美国的发文量位居首位(563篇), 且与英国、加拿大、荷兰、澳大利亚、意大利、德国、瑞士等国家有密切合作; 共计2379个机构发表了相关文献, 发文量最大的机构为安进公司(70篇); 发文最多的作者是来自哈佛医学院附属布列根和妇女医院心肌梗死溶栓研究小组的Giugliano教授(37篇), 被引频次排名第1位的作者是哈佛医学院附属布列根和妇女医院心肌梗死溶栓研究小组的Sabatine教授。该领域研究涉及436个期刊, 其中Journal of Clinical Lipidology是发文量最高的期刊(54篇), New England Journal of Medicine是共被引频次最高的期刊。该领域的研究热点集中于降脂新药PCSK9抑制剂的临床疗效及安全性, 也涉及到传统降脂药物他汀类和依折麦布的临床应用, 其中靶向PCSK9的单克隆抗体以及SiRNA药物因其优越的降LDL-C效果成为近十年的研究重点, 其有效性及长期安全性问题也得到了更多关注。越来越多的临床研究结果推动了血脂管理指南的更新, 为心血管疾病的预防和治疗提供更多思路。

关键词: PCSK9抑制剂, 心血管疾病, 文献计量学, 可视化分析, VOSviewer, CiteSpace

Abstract:

o comprehensively analyze the current research landscape and emerging trends in the application of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treating cardiovascular diseases, a bibliometric analysis was conducted. Relevant English-language literature on PCSK9 inhibitors in cardiovascular treatment, published between January 1, 2013, and December 31, 2023, was retrieved from the Web of Science core collection database. Utilizing tools such as VOSviewer 1.6.20, CiteSpace 6.2.R6, and Excel 2021, the study examined key features of the literature, including annual publication trends, contributing countries/regions, institutions, authors, journals, and key research themes. The analysis identified a total of 1383 articles, revealing a general upward trend in annual publication output. Research in this field has been conducted by 78 countries/regions, with the United States leading in the number of publications (563 articles). The United States also demonstrates strong collaborative networks with other leading countries, including the United Kingdom, Canada, the Netherlands, Australia, Italy, Germany, and Switzerland. In terms of institutional contributions, 2379 institutions have published relevant studies, with Amgen Inc. producing the most publications (n = 70). Among individual contributors, Professor Giugliano from the Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women’s Hospital and Harvard Medical School is the most prolific author, with 37 publications. Meanwhile, Professor Sabatine, also from the TIMI Study Group, holds the highest number of co-citations, underscoring his influence in the field. The analysis also identified 436 journals publishing research on PCSK9 inhibitors, with the Journal of Clinical Lipidology being the most productive (n = 54). However, the New England Journal of Medicine is noted as the journal with the highest co-citation count, indicating its significant impact on this research area. Research hotspots have focused on the efficacy and safety of PCSK9 inhibitors, alongside the clinical application of conventional lipid-lowering therapies such as statins and ezetimibe. Notably, the development of monoclonal antibodies and siRNA-based therapies targeting PCSK9 has gained considerable attention over the past decade due to their superior ability to lower low-density lipoprotein cholesterol (LDL-C). The effectiveness and long-term safety profiles of these novel agents are of growing interest, prompting updates to lipid management guidelines and offering new perspectives for the prevention and treatment of cardiovascular diseases.

Key words: PCSK9 inhibitors, Cardiovascular diseases, Bibliometrics, Visualization, VOSviewer, CiteSpace

Supporting:

王雨, 卢晓静, 岳向峰, 阚琳玮, 杜书章. 基于Web of Science的PCSK9抑制剂在心血管治疗领域相关研究文献计量学分析[J]. 中国药学(英文版), 2025, 34(3): 232-250.

Yu Wang, Xiaojing Lu, Xiangfeng Yue, Linwei Kan, Shuzhang Du. Bibliometric analysis of PCSK9 inhibitors for cardiovascular disease management based on Web of Science[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 232-250.

图/表 12

Figure 1. Annual output and the linear fitting of publication growth of PCSK9 inhibitors in cardiovascular diseases from 2013 to 2023.

Table 1. Top 10 countries/regions and institutions engaged in research on PCSK9 inhibitors for cardiovascular disease treatment.

Figure 2. The network map of countries/regions involved in research on PCSK9 inhibitors for cardiovascular disease treatment.

Figure 3. The network map of institutions involved in research on PCSK9 inhibitors for cardiovascular disease treatment.

Table 2. The top 10 authors and co-cited authors in PCSK9 inhibitor research in cardiovascular disease domain.

Figure 4. A network map of authors and co-cited authors involved in research on PCSK9 inhibitors for cardiovascular diseases.

Table 3. The top 10 journals publishing research on PCSK9 inhibitors for the treatment of cardiovascular diseases.

Table 4. The top 10 co-cited journals in research on PCSK9 inhibitors for the treatment of cardiovascular diseases.

Figure 5. A network map of journals (A) and co-cited journals (B) related to research on PCSK9 inhibitors in cardiovascular diseases.

Table 5. The top 15 co-cited references in research on PCSK9 inhibitors for the treatment of cardiovascular diseases.

Figure 6. A network map of co-cited references in research on PCSK9 inhibitors for cardiovascular diseases.

Figure 7. Top 25 references with a strong citation burst in research on PCSK9 inhibitors for cardiovascular diseases.

参考文献 35

[1]	Stone, N.J.; Robinson, J.; Lichtenstein, A.H.; Merz, C.N.B.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; LEVY, D.; Lloyd-Jones, D.M.; Mcbride, P.; Schwartz, J.S.; Shero, S.T.; Smith, S.C.; Jr, Watson, K.; Wilson, P.W. 2013ACC AHA Guidline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014, 63, 2889–2934.
[2]	Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Group, E.S.D.; Mueller, C.; Drexel, H.; Aboyans, V.; Corsini, A.; Doehner, W.; Farnier, M.; Gigante, B.; Kayikcioglu, M.; Krstacic, G.; Lambrinou, E.; Lewis, B.S.; Masip, J.; Moulin, P.; Petersen, S.; Petronio, A.S.; Piepoli, M.F.; Pintó, X.; Räber, L.; Ray, K.K.; Reiner, Ž.; Riesen, W.F.; Roffi, M.; Schmid, J.P.; Shlyakhto, E.; Simpson, I.A.; Stroes, E.; Sudano, I.; Tselepis, A.D.; Viigimaa, M.; Vindis, C.; Vonbank, A.; Vrablik, M.; Vrsalovic, M.; Zamorano, J.L.; Collet, J.P.; Koskinas, K.C.; Casula, M.; Badimon, L.; John Chapman, M.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J.P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Nibouche, D.; Zelveian, P.H.; Siostrzonek, P.; Najafov, R.; van de Borne, P.; Pojskic, B.; Postadzhiyan, A.; Kypris, L.; Špinar, J.; Larsen, M.L.; Eldin, H.S.; Viigimaa, M.; Strandberg, T.E.; Ferrières, J.; Agladze, R.; Laufs, U.; Rallidis, L.; Bajnok, L.; Gudjónsson, T.; Maher, V.; Henkin, Y.; Gulizia, M.M.; Mussagaliyeva, A.; Bajraktari, G.; Kerimkulova, A.; Latkovskis, G.; Hamoui, O.; Slapikas, R.; Visser, L.; Dingli, P.; Ivanov, V.; Boskovic, A.; Nazzi, M.; Visseren, F.; Mitevska, I.; Retterstøl, K.; Jankowski, P.; Fontes-Carvalho, R.; Dan, G.T.; Ezhov, M.; Foscoli, M.; Giga, V.; Pella, D.; Fras, Z.; de Isla, L.P.; Hagström, E.; Lehmann, R.; Abid, L.; Ozdogan, O.; Mitchenko, O.; Patel, R.S. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur. Heart J. 2020, 41, 111–188.
[3]	Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; Watts, G.F.; Borén, J.; Fazio, S.; Horton, J.D.; Masana, L.; Nicholls, S.J.; Nordestgaard, B.G.; van de Sluis, B.; Taskinen, M.R.; Tokgözoğlu, L.; Landmesser, U.; Laufs, U.; Wiklund, O.; Stock, J.K.; Chapman, M.J.; Catapano, A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017, 38, 2459–2472.
[4]	Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, C.E.; Peralta, C.A.; Saseen, J.J.; Smith, S.C. Jr, Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019, 139, e1082–e1143.
[5]	Ference, B.A.; Graham, I.; Tokgozoglu, L.; Catapano, A.L. Impact of lipids on cardiovascular health JACC health promotion series. J. Am. Coll. Cardiol. 2018, 72, 1141–1156.
[6]	Cunningham, D.; Danley, D.E.; Geoghegan, K.F.; Griffor, M.C.; Hawkins, J.L.; Subashi, T.A.; Varghese, A.H.; Ammirati, M.J.; Culp, J.S.; Hoth, L.R.; Mansour, M.N.; McGrath, K.M.; Seddon, A.P.; Shenolikar, S.; Stutzman-Engwall, K.J.; Warren, L.C.; Xia, D.H.; Qiu, X.Y. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 2007, 14, 413–419.
[7]	Ramachandran, S.; Bhartia, M.; König, C.S. The lipid hypothesis: from resins to proprotein convertase subtilisin/kexin type-9 inhibitors. Front. Cardiovasc. Drug Discov. 2020, 5, 1–35.
[8]	Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34, 154–156.
[9]	Cohen, J.C.; Boerwinkle, E.; Mosley, T.H.; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354, 1264–1272.
[10]	Sabatine, M.S.; Giugliano, R.P.; Wiviott, S.D.; Raal, F.J.; Blom, D.J.; Robinson, J.; Ballantyne, C.M.; Somaratne, R.; Legg, J.; Wasserman, S.M.; Scott, R.; Koren, M.J.; Stein, E.A.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372, 1500–1509.
[11]	Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. Eur. Heart J. 2017, 376, 1713–1722.
[12]	Raal, F.J.; Stein, E.A.; Dufour, R.; Turner, T.; Civeira, F.; Burgess, L.; Langslet, G.; Scott, R.; Olsson, A.G.; Sullivan, D.; Hovingh, G.K.; Cariou, B.; Gouni-Berthold, I.; Somaratne, R.; Bridges, I.; Scott, R.; Wasserman, S.M.; Gaudet, D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015, 385, 331–340.
[13]	Raal, F.J.; Honarpour, N.; Blom, D.J.; Hovingh, G.K.; Xu, F.; Scott, R.; Wasserman, S.M.; Stein, E.A.; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015, 385, 341–350.
[14]	Nicholls, S.J.; Puri, R.S.; Anderson, T.; Ballantyne, C.M.; Cho, L.; Kastelein, J.J.P.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.Y.; Wasserman, S.M.; Scott, R.; Ungi, I.; Podolec, J.; Ophuis, A.O.; Cornel, J.H.; Borgman, M.; Brennan, D.M.; Nissen, S.E. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016, 316, 2373–2384.
[15]	Robinson, J.G.; Farnier, M.; Krempf, M.; Bergeron, J.; Luc, G.; Averna, M.; Stroes, E.S.; Langslet, G.; Raal, F.J.; El Shahawy, M.; Koren, M.J.; Lepor, N.E.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Kastelein, J.J.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. Can. J. Hosp. Pharm. 2015, 372, 1489–1499.
[16]	Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Lecorps, G.; Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Quintero, K.; Roe, M.T.; Sasiela, W.J.; Tamby, J.F.; Tricoci, P.; White, H.D.; Zeiher, A.M.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. Eur. Heart J. 2018, 379, 2097–2107.
[17]	Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.J.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Kastelein, J.J.P.; ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med. 2020, 382, 1520–1530.
[18]	Ray, K.K.; Wright, R.S.; Kallend, D.; Koenig, W.; Leiter, L.A.; Raal, F.J.; Bisch, J.A.; Richardson, T.; Jaros, M.; Wijngaard, P.L.J.; Kastelein, J.J.P.; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. Ann. Intern. Med. 2020, 382, 1507–1519.
[19]	Ray, K.K.; Ray, K.K.; Landmesser, U.; Leiter, L.A.; Kallend, D.; Dufour, R.; Karakas, M.; Hall, T.; Troquay, R.P.; Turner, T.; Visseren, F.L.; Wijngaard, P.; Wright, R.S.; Kastelein, J.J. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 2017, 376, 1430–1440.
[20]	Kokol, P.; Blažun Vošner, H.; Završnik, J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Inf. Libr. J. 2021, 38, 125–138.
[21]	Tran, B.X.; Tran, B.X.; Vu, G.T.; Ha, G.H.; Vuong, Q.H.; Ho, M.T.; Vuong, T.T.; La, V.P.; Ho, M.T.; Nghiem, K.P.; Nguyen, H.L.T.; Latkin, C.A.; Tam, W.W.S.; Cheung, N.M.; Nguyen, H.T.; Ho, C.S.H.; Ho, R.C.M. Global evolution of research in artificial intelligence in health and medicine: a bibliometric study. J. Clin. Med. 2019, 8, E360.
[22]	Lu, X.J.; Jia, X.D.; Si, F.Y.; Yang, X.; Zhang, W.; Yin, Z. Pharmacist-led interventions in older adults: a bibliometric analysis of scientific literature. J. Chin. Pharm. Sci. 2024, 33, 751–765.
[23]	Yang, S.; Sui, J.; Liu, T.; Wu, W.; Xu, S.; Yin, L.; Pu, Y.; Zhang, X.; Zhang, Y.; Shen, B.; Liang, G. Trends on PM_2.5 research, 1997–2016: a bibliometric study. Environ. Sci. Pollut. Res. Int. 2018, 25, 12284–12298.
[24]	van Eck, N.J.; Waltman, L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010, 84, 523–538.
[25]	Synnestvedt, M.B.; Chen, C.M.; Holmes, J.H. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu. Symp. Proc. 2005, 2005, 724–728.
[26]	Lu, C.; Bing, Z.; Bi, Z.; Liu, M.; Lu, T.; Xun, Y.; Wei, Z.; Yang, K. Top-100 most cited publications concerning network pharmacology: a bibliometric analysis. Evid. Based. Complement. Altern. Med. 2019, 2019, 1704816.
[27]	Ke, L.X.; Lu, C.C.; Shen, R.; Lu, T.T.; Ma, B.; Hua, Y.P. Knowledge mapping of drug-induced liver injury: a scientometric investigation (2010–2019). Front. Pharmacol. 2020, 11, 842.
[28]	Lu, C.C.; Liu, M.; Shang, W.R.; Yuan, Y.; Li, M.X.; Deng, X.X.; Li, H.J.; Yang, K.H. Knowledge mapping of angelica sinensis (oliv.) Diels (Danggui) research: a scientometric study. Front. Pharmacol. 2020, 11, 294.
[29]	Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Theroux, P.; Darius, H.; Lewis, B.S.; Ophuis, T.O.; Jukema, J.W.; De Ferrari, G.M.; Ruzyllo, W.; De Lucca, P.; Im, K.; Bohula, E.A.; Reist, C.; Wiviott, S.D.; Tershakovec, A.M.; Musliner, T.A.; Braunwald, E.; Califf, R.M.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372, 2387–2397.
[30]	Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; Simes, J.; Collins, R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. PLoS One. 2010, 376, 1670–1681.
[31]	Huang, X.; Fan, X.; Ying, J.; Chen, S. Emerging trends and research foci in gastrointestinal microbiome. J. Transl. Med. 2019, 17, 67.
[32]	Armitage, J. The safety of statins in clinical practice. Lancet. 2007, 370, 1781–1790.
[33]	Davidson, M.H.; Robinson, J.G. Safety of aggressive lipid management. J. Am. Coll. Cardiol. 2007, 49, 1753–1762.
[34]	Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J.P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Nibouche, D.; Zelveian, P.H.; Siostrzonek, P.; Najafov, R.; Van de Borne, P.; Pojskic, B.; Postadzhiyan, A.; Kypris, L.; Špinar, J.; Larsen, M.L.; Eldin, H.S.; Viigimaa, M.; Strandberg, T.E.; Ferrières, J.; Agladze, R.; Laufs, U.; Rallidis, L.; Bajnok, L.; Gudjónsson, T.; Maher, V.; Henkin, Y.; Gulizia, M.M.; Mussagaliyeva, A.; Bajraktari, G.; Kerimkulova, A.; Latkovskis, G.; Hamoui, O.; Slapikas, R.; Visser, L.; Dingli, P.; Ivanov, V.; Boskovic, A.; Nazzi, M.; Visseren, F.; Mitevska, I.; Retterstøl, K.; Jankowski, P.; Fontes-Carvalho, R.; Gaita, D.; Ezhov, M.; Foscoli, M.; Giga, V.; Pella, D.; Fras, Z.; Perez de Isla, L.; Hagström, E.; Lehmann, R.; Abid, L.; Ozdogan, O.; Mitchenko, O.; Patel, R.S. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019, 290, 140–205.
[35]	Raal, F.J.; Rosenson, R.S.; Reeskamp, L.F.; Hovingh, G.K.; Hovingh, G.K.; Kastelein, J.J.P.; Rubba, P.; Ali, S.; Banerjee, P.; Chan, K.C.; Gipe, D.A.; Khilla, N.; Pordy, R.; Weinreich, D.M.; Yancopoulos, G.D.; Zhang, Y.; Gaudet, D.; ELIPSE HoFH Investigators. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 2020, 383, 711–720.